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ABSTRACT 30 
Pathology consistent with that observed in Alzheimer’s disease (AD) has previously been 31 
documented following intranasal infection of normal wild-type mice with Chlamydia 32 
pneumoniae (Cpn) isolated from an AD brain (96-41). In the current study, BALB/c mice 33 
were intranasally infected with a laboratory strain of Cpn, AR-39, and brain and olfactory 34 
bulbs were obtained at 1-4 months post-infection (pi). Immunohistochemistry for amyloid 35 
beta or Cpn antigens was performed on sections from brains of infected or mock-infected 36 
mice. Chlamydia-specific immunolabeling was identified in olfactory bulb tissues and in 37 
cerebrum of AR-39 infected mice. The Cpn specific labeling was most prominent at 1 38 
month pi and the greatest burden of amyloid deposition was noted at 2 months pi, whereas 39 
both decreased at 3 and 4 months. Viable Cpn was recovered from olfactory bulbs of 3 of 3 40 
experimentally infected mice at 1 and 3 months pi, and in 2 of 3 mice at 4 months pi. In 41 
contrast, in cortical tissues of infected mice at 1 and 4 months pi no viable organism was 42 
obtained. At 3 months pi, only 1 of 3 mice had a measurable burden of viable Cpn from the 43 
cortical tissues. Mock-infected mice (0 of 3) had no detectable Cpn in either olfactory 44 
bulbs or cortical tissues. These data indicate that the AR-39 isolate of Cpn establishes a 45 
limited infection predominantly in the olfactory bulbs of BALB/c mice. Although infection 46 
with the laboratory strain of Cpn promotes deposition of amyloid beta, this appears to 47 
resolve following reduction of the Cpn antigen burden over time. Our data suggest that 48 
infection with the AR-39 laboratory isolate of Cpn results in a different course of amyloid 49 
beta deposition and ultimate resolution than that observed following infection with the 50 
human AD-brain Cpn isolate, 96-41. These data further support that there may be 51 
differences, possibly in virulence factors, between Cpn isolates in the generation of 52 
sustainable AD pathology.    53 
 54 
INTRODUCTION 55 
Alzheimer’s disease (AD) is the most common dementia in the US, accounting for 50 to 70 56 
percent of cases. More than 5 million Americans are living with a diagnosis of AD as of 57 
2013 with 90-95% of cases in the 65 and older segment of the population.  Early stage of 58 
disease involves memory impairment (Fargo and Bleiler. 2014). In the advanced stages of 59 
AD, individuals require assistance with daily activities and, ultimately, in the final stage 60 
become bed-bound and are reliant on around-the-clock care (Hebert, et al. 2003).  AD is a 61 
fatal disorder with the progression from the earliest symptoms to total functional 62 
dependency and death in an untreated person often occurring within 8-10 years post 63 
diagnosis (Fargo and Bleiler. 2014) . 64 
Although much is known about the disease process and progression of AD, the initiating 65 
factors or cause(s) of the disease still remain a mystery. AD has an early onset familial 66 
form that is primarily driven by autosomal dominant genetic alterations in genes encoding 67 
the beta amyloid precursor protein, as well as the loci encoding presenilins 1 and 2 (Goate, 68 
et al. 1991; Levy-Lahad, et al. 1995; Rogaev, et al. 1995; Wolfe. 2007). Transgenic mouse 69 
models have been developed to induce enhanced β-amyloid production and subsequent 70 
deposition of β-amyloid (Hall and Roberson. 2012; Wisniewski and Sigurdsson. 2010), 71 
and serve as models for early onset AD, which accounts for ~3-5 % of all reported cases. 72 
One important issue that cannot be addressed using these model systems is how to target 73 
the early initiating events in sporadic late-onset AD and not just the “tombstone” lesions 74 
that are the result of a long chain of pathological processes (Wisniewski and Sigurdsson. 75 
  
2010). In this regard, animal models that mimic the sporadic late-onset form of AD have 76 
been developed, but these are hampered by the lack of understanding of the primary factors 77 
that promote the deposition of β-amyloid. Currently, models that experimentally induce 78 
AD-like pathology use bacterial toxins such as streptozotocin (Labak, et al. 2010), chronic 79 
stress (Alkadhi, et al. 2010), or colchicine to chemically induce damage (Kumar, et al. 80 
2007) to the CNS to initiate pathology. As several infectious agents, including Chlamydia 81 
pneumoniae (Cpn), have been proposed to enhance risk or play a causal role in AD 82 
(Gerard, et al. 2006; Balin, et al. 1998), animal models have been developed to study the 83 
effects of this infection (Little, et al. 2004; Little, et al. 2005) with regards to AD-like 84 
pathology. However, there remains a dearth of experimental animal systems that 85 
accurately model sporadic late-onset AD, leaving the scientific community with few 86 
options to address key questions related to the initiation/ progression of late-onset disease. 87 
 88 
The identification of Cpn in AD brain tissue (Balin, et al. 1998) was a stimulus to 89 
investigate the potential role that this organism plays in the induction and progression of 90 
late-onset AD and led to the establishment of a mouse model to investigate this occurrence 91 
(Little, et al. 2004). In the original experimental system, BALB/c mice were infected with 92 
Cpn isolated from human AD brain autopsy tissue. The isolate of Cpn, 96-41, was 93 
propagated in HEp-2 cells and then introduced into 3 month old BALB/c mice via 94 
intranasal inoculation; brain tissue was analyzed at monthly time points up through 3 95 
months pi following intranasal delivery. 96 
 97 
Our first study utilized the human AD-brain isolate of Cpn to induce AD-like pathology in 98 
non-transgenic mice (Little, et al. 2004), and was designed to address Koch’s postulates. 99 
The first postulate requires that the infectious organism be isolated from tissues of an 100 
affected individual. In this particular case, the first postulate is satisfied, but for other cases 101 
of the disease this issue is still debate (Itzhaki, et al. 2004). To satisfy Koch’s second 102 
postulate, the pathogen must be isolated from a diseased organism and grown in pure 103 
culture. Cpn was isolated post-mortem from human AD-brain tissue and grown in culture 104 
(although culture required a eukaryotic cell as this is an obligate intracellular bacterium). 105 
Third, the organism was introduced into a mouse, and induced pathology consistent with 106 
AD, while uninfected mice did not display the same pathology. Fourth, the organism was 107 
identified in the tissues of affected mice, but was not re-isolated from the tissue. Thus, 108 
Koch’s postulates were used as a general guide, and although difficult to use in their purest 109 
sense when addressing any intracellular infection, our findings support the hypothesis that 110 
Cpn infection can induce β-amyloid deposition in the brain and contribute directly to 111 
pathogenesis. 112 
 113 
In mice infected with Cpn in our first report, β-amyloid deposits were identified as early as 114 
two months pi, with the greatest number of deposits identified at three months pi. The 115 
number and size of amyloid deposits increased over time, thus the development of AD-like 116 
pathology appeared to be progressive. The experimental induction of mouse derived 117 
β-amyloid deposits in inbred BALB/c mice (not genetically modified) at 5 and 6 months of 118 
age (2 and 3 months pi) indicates that infection can trigger the production and deposition of 119 
β-amyloid in the mouse brain. In contrast, in transgenic mouse models used to study AD, 6 120 
months of age is very early to observe substantial amyloid deposits, yet we observed 121 
  
substantial pathology 2 months after introduction of the infectious agent into 122 
non-transgenic animals. Cpn is a respiratory pathogen and was introduced into mice via an 123 
intranasal inoculation. This is the natural route of infection and the organism can be 124 
responsible for an acute respiratory illness. The respiratory infection appears to precede 125 
dissemination to other organ systems (Little, et al. 2005) and age is an important factor in 126 
the host’s ability to control the dissemination, with even greater spread with the advent of 127 
immunosenescence in older animals. 128 
 129 
In contrast with the initial report associating Cpn with the induction of AD-like pathology 130 
in the brains of BALB/c mice (Little, et al. 2004), the current study was performed with a 131 
respiratory isolate and common laboratory strain of Cpn, AR-39.  The purpose was to 132 
determine if this well-studied laboratory isolate of Cpn would induce pathology in a similar 133 
manner and to the same degree over a similar time course, as that observed for the human 134 
CNS isolate used previously. This approach will inform potential differences in outcomes 135 
when infecting mice with Cpn originally isolated from lung tissues and used as a laboratory 136 
isolate as compared to that from human AD brain.   137 
           138 
MATERIALS AND METHODS 139 
HEp-2 cell line: The human epithelial, HEp-2, cell line (ATCC, Rockville MD) was 140 
maintained in MEM supplemented with 10% fetal bovine serum (FBS) (Cell Gro  141 
Mediatech, Inc, Manassas, VA), 5mM L-Glutamine (Thermo Fisher Scientific, Pittsburgh, 142 
PA) at 37oC and 5% CO2.  1-2 x 10
5 cells were plated in a T25 tissue culture flask 143 
(Thermo Fisher Scientific, Pittsburgh, PA) and passaged as needed prior to collection for 144 
the propagation of Cpn. 145 
 146 
Propagation and purification of Chlamydia pneumoniae: Chlamydia pneumoniae 147 
(Cpn), AR-39 isolate, was obtained from the ATCC (ATCC, Rockville, MD) and 148 
propagated in the HEp-2 cell line similar to the technique described for the Cpn brain 149 
isolate, 96-41(Little, et al. 2004; Campbell, et al. 1991). Prior to infection of BALB/c mice, 150 
homogenates of 72 h culture supernatants and Cpn infected HEp-2 cells were sonicated for 151 
30 seconds and passed through a series of filter membranes with decreasing pore size to 152 
collect the elementary bodies. The organism was resuspended in Hanks Balanced Salt 153 
Solution (HBSS), aliquoted, and stored at -80 C. The quantitation of inclusion forming 154 
units subsequently was determined following infection of HEp-2 epithelial cells with a 155 
series of 10 fold serial dilutions of the concentrated organism. The inclusions were 156 
identified by immunofluorescence using a Chlamydia-specific antibody directly 157 
conjugated to FITC (ImagenTM; DAKO, Carpenteria, CA). Aliquots were diluted in HBSS 158 
to a working concentration for the intranasal infection of mice. 159 
 160 
Mice: Six week old female BALB/cJ mice were purchased from Jackson Laboratories (Bar 161 
Harbor, ME) and acclimated for 2 weeks prior to use. Mice were housed in groups of 2-3 in 162 
HEPA-filter caged racks, with infected mice housed separately from uninfected mice, 163 
within the containment facility at Philadelphia College of Osteopathic Medicine.  All 164 
animal husbandry was performed using Biosafety Level 2 precautions and in a Class II 165 
biosafety cabinet. Mice were fed food and water ad libitum. All animal protocols were 166 
approved by the IACUC at PCOM.  167 
  
 168 
Infection of mice with Chlamydia pneumoniae: Under manual restraint, 8 week old, 169 
female BALB/cJ mice were inoculated intranasally with 5 x 105 inclusion forming units of 170 
the AR-39 isolate of Cpn diluted in 50 µl of HBSS. Six mice were inoculated at 8 weeks of 171 
age for each time point and the brains were analyzed at 1, 2, 3 and 4 months post infection. 172 
Four age and sex matched mice were mock-infected with vehicle alone, HBSS, as a control 173 
for each time point. At each time point, 3 experimentally-infected and 2 mock-infected 174 
control mice were anesthetized, cardiac-perfused and organs were collected and immersion 175 
fixed in 4 % paraformaldehyde for embedding, sectioning and immunohistochemical 176 
analysis. The remaining 3 experimentally-infected and 2 mock-infected control mice at 177 
each time point other than for 2 month animals for which frozen tissue was not available 178 
were euthanized and organs were collected and snap-frozen in liquid nitrogen and then 179 
stored at -80 C until analysis for detection and quantification of viable organism.   180 
 181 
Recovery and quantification of Chlamydia pneumoniae: Quantification of viable Cpn 182 
was performed in an identical manner to our previous report (Little et al 2005) (Little, et al. 183 
2005) in the following manner. Frozen tissue was thawed and a 10% weight to volume 184 
homogenate was prepared in serum-free minimal essential medium (MEM) (Thermo 185 
Fisher Scientific, Pittsburgh, PA) supplemented with 2mM Glutamine. Serial ten-fold 186 
dilutions (in 200µL) were added to 4 well Lab Tech chamber slides (Naperville, IL) on 187 
which HEp-2 cells were previously plated. Negative control wells contained cells 188 
mock-infected with medium alone. The chamber slides were incubated at 37oC in 5% CO2 189 
for 2.5 hrs, washed with HBSS and refilled with fresh complete medium supplemented 190 
with 2µg/ml cycloheximide (Sigma-Aldrich, St. Louis, MO) followed by incubation for 48 191 
hrs at 37oC. After incubation, slides were washed with HBSS, fixed in 50% methanol at RT 192 
for 20 min, washed twice in HBSS, and labeled with a 1:10 dilution of FITC-conjugated 193 
Chlamydia-specific antibody (ImagenTM; DAKO, Carpenteria, CA) for 90 min in the dark 194 
at 37°C. Slides were washed in phosphate buffered saline (PBS) and counterstained with a 195 
2 µg/ml of bisBenzamide (Sigma-Aldrich, St. Louis, MO) in PBS for 1 min, washed in 196 
PBS and coverslipped with aqueous mounting medium (ImagenTM; DAKO, Carpenteria, 197 
CA). All titers are calculated as inclusion forming units (IFU)/ml of 10% weight to volume 198 
tissue homogenate. 199 
 200 
Antibodies: The following Chlamydia-specific antibodies were generated in mice: 201 
RDI-PROAC1p (Research Diagnostics Incorporated, Flanders, NJ) (AC1P) (monoclonal 202 
IgG) specific for Chlamydia lipopolysaccharide used at a dilution of 1:10 (5µg/ml), M6600 203 
(DakoCytomation, Carpinteria, CA) (monoclonal IgG) specific for Cpn major outer 204 
membrane protein used at a dilution of 1:10 (10µg/ml), and 10C-27 (Fitzgerald, Concord, 205 
MA) (monoclonal IgG) specific for Cpn used at a dilution of 1:100 (1µg/ml). Additionally, 206 
B65256R (Biodesign International, Saco, ME) (B56R) specific for Chlamydia purified 207 
elementary bodies was generated in rabbit and used at a dilution of 1:200 (2µg/ml). Both 208 
secondary antibodies specific for either mouse, AP-Goat anti-mouse IgG conjugate 209 
(Zymed Laboratories, San Francisco, CA), or rabbit, AP-Goat anti-rabbit IgG conjugate 210 
(Zymed Laboratories, San Francisco, CA), were used at a concentration of 2 µg/ml.  All 211 
antibodies were diluted to working concentration in 2% FBS/PBS blocking buffer (Thermo 212 
Fisher Scientific, Pittsburgh, PA). For the detection of Aβ amyloid, the following 213 
  
antibodies were used at a recommended concentration of 2 µg/ml: a rabbit polyclonal 214 
antibody specific for the carboxyl-terminal fragment of Aβ amyloid 1-42 (catalogue: 215 
A1976 Oncogene Research Products, Boston, MA), and a mouse monoclonal antibody 216 
(4G8) to the 17-24 amino acid peptide of human Aβ amyloid 1-42 (catalogue:9220-05 217 
Signet Laboratories Inc., Dedham, MA). For all amyloid specific immunolabeling, 218 
secondary antibodies consisted of HRP conjugated sheep anti-Mouse IgG (H + L) or 219 
donkey anti-rabbit IgG (H + L). Antibodies were used at a dilution of 1:300 as 220 
recommended by the supplier (Amersham Biosciences, Piscataway, NJ and Life 221 
Technologies, Inc, Grand Island, NY).  222 
 223 
Immunohistochemistry: Brain sections from experimental and control mice were 224 
immunolabeled for Aβ amyloid or Cpn antigen at 1, 2, 3, and 4 months post infection using 225 
the aforementioned antibodies. Coronal sections were deparaffinized with xylene (Thermo 226 
Fisher Scientific, Pittsburgh PA) rehydrated in a series of graded alcohol solutions 227 
(Electron Microscopy Sciences, Fort Washington, PA), followed by de-ionized (DI) H2O.  228 
Slides were then placed in Citra antigen retrieval buffer (BioGenex, San Ramon, CA) and 229 
steamed in a 2100 Retriever (Pick Cell Laboratories, Amsterdam, Netherlands) for 20 min 230 
at high pressure and temperature (120° C). Slides were then rinsed with PBS pH 7.4 231 
(Sigma-Aldrich, St Louis, MO) 3 x 5 minutes. Endogenous peroxidase activity was 232 
quenched utilizing a 3% solution of H2O2/PBS (Thermo Fisher Scientific, Pittsburgh, PA) 233 
for 5 min at RT. Sections were rinsed 1 x 5 min in PBS and blocked 3 x in 2% heat 234 
inactivated fetal bovine serum (FBS)/PBS. A total of 30 coronal brain sections, 10 sets of 3 235 
sections (1 per antibody), were immunolabeled per mouse. The sections were spaced 236 
equally (approximately every 70-100 microns in brain tissue) from rostral (bregma + 237 
2.22mm) to caudal (bregma -5.88mm) in order to provide samples representative of the 238 
regions spanning the entire brain of each mouse. Slides receiving Chlamydia-specific 239 
primary antibodies B56R or a cocktail of 10C-27, AC1P, M6600 were applied to tissue 240 
sections and placed in a humidified chamber at 37 °C for 90 min. The sections were rinsed 241 
3 x 5 min each and then blocked 3 x 15 min each in 2% FBS/PBS, and incubated with 242 
appropriate secondary antibodies in a humidified chamber for 1 hour at 37 °C. Following 243 
incubation, sections were rinsed with DI H2O 3 x 5 min and developed using alkaline 244 
phosphatase new magenta for 15 min (BioFX, Owings Mills, MD) at RT. Sections were 245 
rinsed in DI H2O 3 x 5 min followed by one PBS rinse for 5 min. Acidified Harris’s 246 
Hematoxylin (Thermo Fisher Scientific, Pittsburgh, PA) was applied to sections for 1 min. 247 
One DI H2O rinse followed counterstaining and the sections were contrasted in PBS for 5 248 
min. Finally, the sections were rinsed with DI H2O 3 x 5 min, air dried, and crystal 249 
mounted (BioMeda, Foster City, CA). Once dry, the sections were permounted and 250 
coverslipped.  251 
 252 
Slides receiving mouse primary antibodies were blocked in mouse on mouse (M.O.M.) 253 
IgG blocking reagent (Vector M.O.M. kit, Vector Laboratories, Burlingame, CA) for 1 hr 254 
at RT, rinsed, and incubated for 5 min in the M.O.M. blocking buffer. For all sections, the 255 
primary antibodies were incubated overnight at 40C. The sections were rinsed in PBS 3 x 256 
for 5 min each, blocked 3 x for 15 min each in 2% FBS/PBS, and incubated with 257 
appropriate secondary antibodies in a humidified chamber for 2 h at RT. The sections 258 
labeled with anti-amyloid antibodies were rinsed with PBS 3 x for 10 min each and 259 
  
visualized with 3, 3’-Diaminobenzidine (DAB) (Sigma FASTTM, Sigma-Aldrich, St. Louis, 260 
MO). Sections were rinsed with dH2O, counterstained with Harris’ Alum Hematoxylin 261 
(EM Sciences HarlecoR, EM Industries, Inc., Hawthorne, NY), and permounted.  262 
  263 
Microscopic Analysis: Digital images were captured using Image-Pro Plus Phase 3 264 
Imaging System software (Media Cybernetics, Silver Spring, MD) on a Nikon Eclipse 265 
E800 microscope using a Spot RT Camera (Diagnostic Instruments, Sterling Heights, MI).   266 
 267 
Statistical Analysis: 268 
Statistical analysis was performed using the student t-test followed by pair-wise testing of 269 
uninfected (n=8) relative to each experimental infected timepoint (n=3) using Microsoft 270 
excel statistical analysis software and P values of < 0.05 which were considered 271 
significant. 272 
 273 
RESULTS 274 
Recovery of infectious Chlamydia pneumoniae from olfactory bulbs and cerebrum: 275 
Olfactory bulbs and cerebral tissues were dissected from BALB/c mice following 276 
euthanization, snap frozen, and homogenized prior to incubation with HEp-2 cells in 277 
culture to determine if detectable levels of viable Cpn could be recovered from the central 278 
nervous system. Ten-fold serial dilutions of the homogenized tissues were incubated with 279 
HEp-2 cells to determine the amount of viable infectious Cpn present in the tissues at 1, 3 280 
and 4 months pi. Tissue from the 2 month animal was not available. Infectious Cpn was 281 
recovered and quantified from 3 of 3 olfactory bulbs at 1 month pi, ranging from 3 x 103 to 282 
3 x 105 IFU/ml of tissue homogenate (Fig 1a). At 3 months pi, Cpn was detected in 3 of 3 283 
olfactory bulbs with a range of 2 x 105 to 3 x 106 IFU/ml of tissue homogenate (Fig 1a). At 284 
4 months, Cpn was detected in 2 of 3 olfactory bulbs with a range of 0 to ~2 x 106 IFU/ml 285 
tissue homogenate (Fig. 1a). Of the 3 olfactory bulbs tested from the mock infected 286 
animals, no Cpn was recovered. In contrast to the olfactory bulbs, Cpn was not recovered 287 
from the brain tissue (cerebrum) at 1 and 4 months pi, although at 3 months, Cpn was 288 
recovered and quantified at 3 x 104 IFU/ml of tissue from 1 of 3 brains (Fig. 1b). This same 289 
mouse had 3 x 105 IFU/ml in the olfactory bulb as noted above. With regards to brain 290 
tissues analyzed from the 3 control animals, no Cpn was detected.    291 
  292 
Identification and distribution of Chlamydia pneumoniae antigen in the central 293 
nervous system: Cpn antigen was detected in olfactory bulb tissues at 1 and 3 months pi 294 
using antibodies specific for Cpn LPS and outer membrane proteins. Representative 295 
immunolabeling for Cpn in these tissues at 1 month pi was principally intracellular (Fig.2). 296 
The labeling profiles consisted of large intracellular vacuoles, often perinuclear with 297 
prominent well-defined inclusions. Furthermore, Cpn antigen labeling (LPS and outer 298 
membrane proteins) was documented within the cerebrum with a quantitative analysis of 299 
10 total slides per animal distributed rostral to caudal with distances measured from 300 
Bregma (Table 1). Intracellular immunolabeling was observed to be both perinuclear and 301 
diffuse in the cytoplasm with very few clearly documentable intracellular inclusions (Fig. 302 
3). However, upon close examination, punctate immunolabeling was observed in 303 
numerous cells (Fig. 3c,e). 304 
 305 
  
Table 1: Location of Chlamydia pneumoniae immunoreactivity and Aβ 1-42 amyloid 306 
deposits over 4 months post infection within brains of Cpn-infected mice.  (A) The 307 
location and number of immunoreactive amyloid deposits or Cpn antigen is designated in 308 
millimeters (section location in mm) rostral or caudal to the mouse bregma. (B) Statistical 309 
analysis of Cpn-specific immunoreactivity and Aβ 1-42 immunoreactive depostis from 310 
infected and uninfected mouse brains. For each time point, N = animals analyzed, * 311 
indicate statistical significance.  312 
 313 
Table 1 314 
A 315 
   
  Bregma 
     
Total 
2.22 1.7 0.38 -1.28 -2.75 -3.8 -4.92 -5.46 -5.88 Inf Un 
1 Mo Cpn  10 22 18 23 42 9 6 2 154 24 22 
Amyloid  1 0 3 3 0 2 1 0 10 0 0 
2 Mo Cpn  15 19 5 26 21 20 10 0 134 14 18 
Amyloid  30 11 16 31 43 35 6 0 180 12 8 
3 Mo Cpn  11 13 22 5 9 9 4 7 91 10 11 
Amyloid  9 14 7 4 3 3 11 2 53 10 0 
4 Mo Cpn  11 13 15 13 10 10 1 3 76 9 0 
Amyloid  0 3 6 3 1 5 1 0 19 5 0 
Cpn 51 47 67 60 67 82 48 21 12 455 57 
Amyloid 8 33 12 5 32 19 33 1 0 143 27 
 316 
B 317 
 318 
  Chlamydia-specific immunoreactivity 
 
Amyloid deposits 
    
   
    
   
  
  uninfected n=2 infected n=3   uninfected n=2 infected n=3 
time p.i. mean s.d. mean s.d. time p.i. mean s.d. mean s.d. 
1 12 5.65 51.33* 32.01 1 0 0 3.33 1.167 
  
  
      
  
    
2 7 2.83 44.67* 33.56 2 6 1 60* 8 
  
  
      
  
    
3 5 1.41 30.33* 12.06 3 5 1 17.67* 0.67 
  
  
      
  
    
4 4.50 0.71 25.33 24.21 4 2.5 1.5 6.33 2.167 
  
  
      
  
    
ALL 7.13 4.02 37.92 21.22 ALL 3.38 2.28 21.83 19.08 
 319 
Quantitative analysis of Cpn antigen in the brain at 1 through 4 months post-intranasal 320 
inoculation revealed peak Cpn antigen burden (154 immunoreactive profiles) at 1 month 321 
(Table 1A). Cpn-specific immunoreactivity demonstrated a step-wise decrease at 2, 3, and 322 
4 months pi with 134, 91, and 76 immunoreactive profiles, respectively. With regards to 323 
specific coordinates in the brain, the greatest Cpn antigen burden (ie, 42 Cpn 324 
immunoreactive profiles) was documented at 1 month in multiple sections 3.8 mm caudal 325 
  
to bregma. These sections contain the entorhinal cortex, perirhinal cortex, hippocampus, 326 
and amygdala, all regions affected in Alzheimer’s disease. A low but detectable number of 327 
non-specific Cpn immunoreactive sites were detected within mock-infected control mouse 328 
brain tissue with an average number of 0.355/section analyzed. The mean number of 329 
immunoreactive sites identified was 7.125/ mouse +/- 4.01 and based upon the results of 330 
the student t-test a statistically significant difference (p< 0.05) was observed between 331 
experimentally infected tissue and mock-infected control mouse tissue at all timepoints 332 
analyzed; 1 month p.i. (51.33 +/- 32.01), 2 months p.i. (44.67 +/- 33.56), and 3 months 333 
p.i.(30.33 +/- 12.06). No statistically significant difference was observed in the 4 month 334 
p.i. (25.33 +/- 24.21) experimental group relative to uninfected control tissue (Table 1 B).  335 
     336 
Identification and distribution of amyloid antigen in the central nervous system 337 
Antibodies specific for amyloid beta 1-40 (Aβ1-40) and amyloid beta 1-42 (Aβ1-42) were 338 
used to determine if immunoreactive deposits could be detected in mock infected controls 339 
and experimentally infected BALB/c mice. A limited number of Aβ1-40 immunoreactive 340 
deposits were observed exclusively in the brains of experimentally infected mice at 2 341 
months post-infection (data not shown). No Aβ1-40 deposits were detected in the brains of 342 
any control mice at any timepoint nor in experimentally infected mice at 1, 3 and 4 months 343 
post infection.  344 
 345 
Quantiative analysis of amyloid burden revealed the highest number of Aβ 1-42 346 
immunoreactive deposits (43) at 2 months pi 3.8 mm caudal to bregma, similar to Cpn 347 
immunoreactivity at 1 month pi (Table 1A).  Overall Aβ 1-42 immunoreactivity was 348 
greatest at 2 month pi, having been minimal at 1 month pi and decreasing at 3 and 4 months 349 
pi. As noted above, these sections contain the entorhinal cortex (Ect), perirhinal cortex 350 
(Prh), cerebral peduncle (Cp), hippocampus, and amygdala, all regions affected in 351 
Alzheimer’s disease (see Fig 4 for Aβ 1-42 immunoreactive deposits). A low but 352 
detectable number of amyloid-specific immunoreactive sites were detected within 353 
mock-infected control mouse brain tissue at 2, 3, and 4 months p.i. with an average number 354 
of 0.17/section analyzed. The mean number of immunoreactive sites identified was 3.38/ 355 
mouse +/- 2.28 and based upon the results of the student t-test a statistically significant 356 
difference (p< 0.05) was observed between experimentally infected tissue and 357 
mock-infected control mouse tissue at 2 months p.i. (60/mouse +/- 8) and 3 months p.i. 358 
(17.67 +/-0.67). No statistically significant difference was detected at 1 month p.i. (3.33 +/- 359 
1.17) or 4 months p.i. (21.83 +/- 19.08) (Table 1 B).  360 
 361 
DISCUSSION 362 
This study was designed as a follow-up investigation to the initial report of experimental 363 
induction of AD-like pathology in BALB/c mice following intranasal inoculation with C 364 
pneumoniae (Little, et al. 2004). The key difference in the current study as compared to 365 
that by Little et al 2004 was that the AR39 respiratory lab strain was used to evaluate the 366 
effects in the brain as compared to the 96-41 brain strain used in the initial report. 367 
Chlamydia- specific immunolabeling was identified in olfactory bulb tissues and in brains 368 
(cortical tissues) of AR-39-infected mice. The Cpn-specific labeling was most prominent 369 
at 1 month post-infection (pi) and the greatest burden of amyloid deposition was noted at 2 370 
months pi, whereas both decreased at 3 and 4 months pi. The majority of amyloid deposits 371 
  
at these times were immunoreactive for Aβ 1-42. Interestingly, a limited number of Aβ 372 
1-40 immunoreactive deposits also was identified (data not shown), but only at the 2 month 373 
time point, the time of peak amyloid burden. Viable Cpn was recovered from the olfactory 374 
bulb tissues of 3 of 3 experimentally infected mice at 1 and 3 months pi, and 2 of 3 at 4 375 
months pi. In contrast, in cerebral cortical tissues of experimentally infected mice, only at 3 376 
months pi did 1 of 3 mice have a measurable burden of viable Cpn. Mock-infected control 377 
mice had no detectable Cpn in either olfactory bulbs (0 of 3) or cortical tissues (0 of 3). 378 
These data indicate that, following intranasal infection, the AR-39 respiratory isolate of 379 
Cpn establishes a limited infection predominantly in the olfactory bulbs of BALB/c mice. 380 
Furthermore, although infection with the laboratory strain of Cpn promotes deposition of 381 
Aβ amyloid, this appears to resolve following reduction of the Cpn antigen burden over 382 
time.   383 
 384 
In our current study, brains were analyzed at 1 through 4 months pi by immunohisto- 385 
chemistry with antibodies specific for Chlamydia antigen and antibodies specific for 386 
Aβ-amyloid 1-42. Similar to the initial report utilizing the 96-41 human AD-brain isolate, 387 
no substantial amyloid deposits were observed at 1 month pi and a limited degree of 388 
AD-like pathology was identified at 2 months pi with AR-39. In contrast to the original 389 
study utilizing the brain isolate, at 4 months pi AD-like pathology was comparable to that 390 
observed in mock infected mice and infected mice at 1 month pi, suggesting that the degree 391 
of pathology had decreased between 2 through 4 months pi. Identification and quantitative 392 
analysis of Chlamydia antigen burden indicated that peak Chlamydia antigen burden 393 
preceded peak amyloid deposition. The greatest Chlamydia antigen burden in brains of 394 
infected BALB/c mice was noted at 1 month pi, and decreased at 2 through 4 months pi, 395 
whereas peak amyloid burden was at 2 months pi, and decreased thereafter. Taken 396 
together, the burden of Chlamydia antigen and number of amyloid deposits suggests that 397 
Cpn infection serves as a primary stimulus for Aβ-amyloid processing and deposition in 398 
brain tissues. While consistent co-localization of amyloid with Chlamydia antigen was not 399 
apparent, both were present in the same regions at times consistent with AD-like 400 
pathology. As the course of infection preceded the course of pathology development, 401 
infection may serve as a stimulus for inflammation as well as for beta amyloid production 402 
and deposition. Precedence for infection in exacerbating AD-like pathology has been 403 
reported for other types of infections in different animal models (McManus, et al. 2014; 404 
Wang, et al. 2014). Once the infection has been controlled or resolved completely, levels 405 
of soluble amyloid apparently decrease presumably following internalization by glial cells 406 
(Hawkes, et al. 2012) and/or washout into the blood, thereby resulting in fewer deposits 407 
documented at the 3 and 4 month timepoints. These findings support our contention that 408 
laboratory strains of Cpn from respiratory infections as compared to Cpn brain isolates are 409 
less capable of creating long-standing damage in the CNS. In this regard, at the present 410 
time, we do not know what inoculum of Cpn is sufficient to not only initiate but to promote 411 
chronic human disease, nor do we understand potentially different virulence factors of Cpn 412 
isolated from different tissue sites. Our animal studies do support our contention that 413 
infection (even in modest titers - 105 organisms), specifically through an intranasal route, 414 
can initiate changes in the brain consistent with early AD-like pathology. 415 
 416 
In mice infected with the 96-41 Cpn brain isolate, Aβ-amyloid deposits were identified as 417 
  
early as two months pi, with the greatest number of deposits identified at three months pi. 418 
As the number and size of amyloid deposits increased over time, the development of 419 
AD-like pathology appeared to be progressive. This is an important issue as early initiating 420 
events resulting in sporadic late-onset AD have not been addressed using genetically 421 
modified transgenic models that principally emulate familial AD, not the more common 422 
late-onset form of disease. Furthermore, animal models that mimic the sporadic late-onset 423 
form of AD have been hampered by the lack of understanding of the primary factors that 424 
promote the early deposition of Aβ-amyloid, however numerous experimentally induced 425 
animal models utilizing direct injection of microbial products have been shown to induce 426 
transient amyloid production and deposition (Krstic, et al. 2012; Erickson, et al. 2012). 427 
Our current study with a respiratory isolate of Cpn supports the induction of transient 428 
amyloid deposition and contrasts with our previous work suggesting that a brain isolate of 429 
Cpn results in progressive amyloid accumulation. 430 
 431 
Interestingly, a previous study did not identify substantial AD-like pathology in the brain 432 
following infection with a respiratory isolate/laboratory strain of Cpn (TWAR 2043) 433 
(Boelen, et al. 2007). Boelen and co-workers infected BALB/c mice, via intranasal 434 
inoculation, and examined brain tissue at one and three months pi based upon the 435 
assumption that TWAR 2043 and the human AD brain isolate 96-41 used by Little et al, 436 
2004 would both induce a progressive pathology following infection. The number of 437 
amyloid beta deposits was reported as 1 or 2 aggregates per section without a preference 438 
for a certain brain region in the Boelen et al study, and the researchers indicated that Cpn 439 
was not detected in the CNS at 1 or 3 months pi. In addition, both mock-infected and Cpn 440 
infected mice displayed no difference in amyloid deposits. The clear difference noted from 441 
the Little et al 2004 study of number and size of deposits was notably different from the 442 
Boelen et al report. Boelen et al noted that these discrepancies could be due to the fact that 443 
the TWAR 2043 Cpn strain used may have different virulence properties than the human 444 
AD-brain isolate, 96-41. TWAR 2043 and 96-41 display different phenotypes with respect 445 
to the ability to establish a persistent infection and the subsequent induction of pathology 446 
within the brains of BALB/c mice.  447 
 448 
Our current findings support the contention that isolates of Cpn may differ in their ability to 449 
establish chronic or persistent infection and promote progressive pathology. Numerous 450 
questions remain as to the nature of the organisms that typically infect the human 451 
population. Pertinent issues, just to name a few, include: risk factors promoting infection at 452 
specific sites in the body, spread into different tissues and organs following initial 453 
infection, virulence factors expressed by the organism and/or host response, and age at 454 
which infection occurs. With regards to age, a prior study of Cpn infection in older animals 455 
suggests that older age at time of infection promotes the establishment of a brain infection 456 
(Little, et al. 2005). Further, to address our current study that a modest inoculum of a 457 
respiratory isolate of Cpn initiated specific but non-sustainable change in the brain 458 
following intranasal inoculation, we preliminarily inoculated a small group of animals with 459 
Cpn AR-39, either twice (days 0 and 30), or three times (days 0, 30 and 60) and sacrificed 460 
at day 90, and found that individual BALB/c mice inoculated twice displayed 68 amyloid 461 
deposits and those inoculated 3 times had 177 amyloid deposits (unpublished 462 
observations). In comparison, mice receiving only a single intranasal inoculation as 463 
  
observed in the current study at 3 months pi had an average of ~17 - 18 deposits (53 464 
deposits/3 mice) (see table 1A). These preliminary observations would suggest that 465 
multiple inocula of Cpn may exacerbate pathology in the brain, but further experiments are 466 
required to clarify this. Furthermore, respiratory or blood-borne organisms may become 467 
altered after invading different tissue sites including the brain and this may reflect biovar 468 
and serovar differences with Cpn, although this remains to be determined. Future 469 
sequencing analyses and specific characterization of different tissue and organ isolates 470 
may help to resolve these issues.  471 
 472 
In summary, host immune responses that limit or reduce Cpn replication and antigen 473 
burden may effectively decrease Cpn as a primary stimulus for long-term production of 474 
Aβ-amyloid in our experimental system. We propose that the difference in progressive 475 
versus non-progressive AD-like pathology is due to as yet uncharacterized differences 476 
between human AD-brain adapted isolates such as 96-41, and the respiratory isolates/ 477 
laboratory strains TWAR 2043 and AR-39. This implies that there are different virulence 478 
factors including tissue tropism for different isolates of Cpn. Thus, the ability of the 479 
organism to enter and persist in the central nervous system and potentiate a chronic 480 
inflammatory response may be critical to its role in the initiation and maintenance of AD 481 
pathogenesis.     482 
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 582 
Figure 1. Recovery of viable Chlamydia pneumoniae from olfactory bulb and brain tissues 583 
following intranasal infection. (A) At 1, 3 and 4 months post-infection, viable Cpn was 584 
recovered from olfactory bulb tissue homogenates of 8 BALB/c mice, 3 of 3 mice at one 585 
month pi, 3 of 3 mice at 3 months pi, and 2 of 3 mice at 4 months pi. (B) In contrast, only 1 586 
mouse demonstrated viable Cpn from cerebral cortical tissue at any time; that being 1 587 
mouse at 3 months pi. Viable Cpn was quantified as infectious forming units /ml of tissue 588 
homogenate. 589 
Figure 2.  Chlamydia pneumoniae specific immunoreactivity in olfactory bulbs. Cpn 590 
(AR-39) antigens were detected in olfactory bulb tissues at 1 month post-infection 591 
following intranasal inoculation (arrows). A, B and C, D are representative images from 2 592 
different mice infected with Cpn and labeled with a cocktail of anti-Cpn antibodies 593 
(RDI-PROAC1p, M6600, 10C-27). E, F are representative images from mock infected 594 
mice comparably immunolabeled. Mag bars A-F = 50µm. 595 
Figure 3. Chlamydia pneumoniae specific immunoreactivity in the central nervous 596 
system. Representative images of Cpn-specific antigen labeling in the brains of infected 597 
mice at 1 month (panels A and B), 3 months (panels C and D), and 4 months (panels E and 598 
  
F) post infection. The upper right corner of each image is a higher magnification image of 599 
Cpn-specific antigen labeling as designated by the low magnification arrow. Mag bars = 600 
50µm. 601 
Figure 4. Beta amyloid Aβ 1-42 deposits in the CNS at 2 months pi following intranasal 602 
infection with Chlamydia pneumoniae AR-39. Brains were examined by light microscopy 603 
for the presence of Aβ 1-42 using a specific anti-Aβ 1-42 antibody. (A-E) Representative 604 
images of Aβ 1-42-specific labeling (arrowheads) are shown within different regions of 605 
this brain section. Ect (Entorhinal cortex), L Ent (Lateral entorhinal cortex), Th 606 
(Thalamus), Prh (Perirhinal cortex), Cp (Cerebral peduncle). Mag bars (A) 100 µm (B-E) 607 
20 µm. 608 
 609 
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